BearWorks
MSU Graduate Theses
Summer 2015

Investigation of Nocifensive and Cellular Effects of
Dihydroergotamine in a Model of Chronic Migraine
Jennifer Elise Denson

As with any intellectual project, the content and views expressed in this thesis may be
considered objectionable by some readers. However, this student-scholar’s work has been
judged to have academic value by the student’s thesis committee members trained in the
discipline. The content and views expressed in this thesis are those of the student-scholar and
are not endorsed by Missouri State University, its Graduate College, or its employees.

Follow this and additional works at: https://bearworks.missouristate.edu/theses
Part of the Biology Commons

Recommended Citation
Denson, Jennifer Elise, "Investigation of Nocifensive and Cellular Effects of Dihydroergotamine in a Model
of Chronic Migraine" (2015). MSU Graduate Theses. 1350.
https://bearworks.missouristate.edu/theses/1350

This article or document was made available through BearWorks, the institutional repository of Missouri State
University. The work contained in it may be protected by copyright and require permission of the copyright holder
for reuse or redistribution.
For more information, please contact BearWorks@library.missouristate.edu.

INVESTIGATION OF NOCIFENSIVE AND CELLULAR EFFECTS OF
DIHYDROERGOTAMINE IN A MODEL OF CHRONIC MIGRAINE

A Masters Thesis
Presented to
The Graduate College of
Missouri State University

In Partial Fulfillment
Of the Requirements for the Degree
Master of Science, Biology

By
Jennifer E. Denson
July 2015

Copyright 2015 by Jennifer Elise Denson

ii

INVESTIGATION OF NOCIFENSIVE AND CELLULAR EFFECTS OF
DIHYDROERGOTAMINE IN A MODEL OF CHRONIC MIGRAINE
Biology
Missouri State University, July 2015
Master of Science
Jennifer E. Denson
ABSTRACT
The goal of my study was to investigate the nocifensive behavioral and cellular effects of
dihydroergotamine (DHE) and sumatriptan in a model of sustained trigeminal activation.
Trigeminal nerves provide sensory innervation to the head and face and their activation
has been implicated in migraine pathology. The most commonly prescribed medications
for migraine treatment are the triptan class of drugs. However, triptans are not an
effective therapy for all migraine patients and some develop triptan resistance. Ergotderivatives, including DHE, could be a potential alternative for this subpopulation of
patients. To cause activation of the trigeminal system, adult male Sprague Dawley rats
were given an inflammatory injection of complete Freund’s adjuvant (CFA) or saline as a
vehicle control in the temporomandibular joint capsule. Three and four days post-CFAinjection, intraperitoneal injections of DHE, sumatriptan, or vehicle control were
delivered. I found that DHE, but not sumatriptan, was able to transiently inhibit CFAmediated increases in nocifensive withdrawal behavior. Within the spinal cord, DHE was
shown to inhibit CFA stimulated levels of the signaling protein PKA, which is known to
promote central sensitization, and Iba1, a marker of activated microglial cells. However,
both DHE and sumatriptan were able to inhibit stimulated levels of GFAP, a protein used
as a marker of activated astrocytes. Results from my study provide evidence that DHE,
but not sumatriptan, can inhibit nociception caused by prolonged activation of trigeminal
neurons and the inhibitory effect is likely to involve suppressing development of central
sensitization. I propose that DHE may be therapeutically beneficial by blocking ongoing
peripheral and central sensitization as characteristic of frequent episodic and chronic
migraine.
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INTRODUCTION

Pathology of Migraine
Migraine is characterized by a severe, debilitating headache that can be
accompanied by somatic symptoms such as nausea, vomiting, sensitivity to light, sound,
or odors, and visual disturbances known as auras. Migraine affects 16.6-22.7% of adults
in the United States, occurring three times more often in females than males (Schwedt,
2014). Chronic migraine (defined as having a headache for 15 days a month for the
previous three months) comprises 7.7% of all migraine cases and, as compared with
episodic migraine, results in significantly more severe disability for the patient as well as
a higher co-morbidity with depression and anxiety (Smitherman et al., 2013). Risk factors
for episodic migraine progressing into chronic migraine include caffeine use, medication
overuse, obesity, snoring or sleep apnea, psychiatric conditions, and stressful life events
(Dodick, 2009).
Historically, migraine has been viewed as a vascular disease but research in the
last few decades suggests that migraine has a strong neurological basis and it is now
believed that sensitization and activation of the trigeminal nerve, the fifth cranial nerve,
which provides sensory innervation of much of the head and face, underlies migraine
pathology (Pietrobon and Moskowitz, 2013). One proposed mechanism for this
activation begins with cortical spreading depression (CSD), a period of enhanced
neuronal activity that moves across the cortex, followed by a period of very low cortical
neuronal activity (Xu et al., 2010). The enhanced neuronal activity results in excessive
extravasation of proteins and ions into the perivascular space that triggers vasodilation of
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the meninges, including the middle meningeal artery (MMA), and subsequently causes
excitation of trigeminal afferent neurons. Upon activation, these neurons release
inflammatory neuropeptides like calcitonin gene-related peptide (CGRP) and substance P
into the meninges as well as transmitting nociceptive signals centrally to the spinal
trigeminal nucleus (STN). Within the spinal cord, these neuropeptides activate
parasympathetic pathways to release additional vasoactive and inflammatory molecules
into the meninges, further increasing blood flow and sustaining neurogenic inflammation
(Bolay et al., 2002). These events can lead to both peripheral and central sensitization,
which are characterized by the lowering of the stimulus threshold required to elicit a
neuronal response. Sensitization of nociceptive neurons disproportionately increases
migraine pain (hyperalgesia), causes pain responses to normally non-painful stimuli
(allodynia), and prolongs the migraine attack (Dodick and Silberstein, 2006).

The Trigeminal System
The afferent sensory neurons of the trigeminal nerve are pseudounipolar with
their cell bodies located in the trigeminal ganglion (TG). These neurons have peripheral
processes that extend to the head and face and central processes that synapse with second
order neurons in the spinal trigeminal nucleus (STN) of the upper spinal cord (Fig. 1).
These fibers are either lightly myelinated Aδ fibers or unmyelinated C fibers that respond
to thermal, mechanical, and chemical stimuli to relay nociceptive information to the
central nervous system (CNS) (Devor, 1999, Rathee et al., 2002). These peripheral
neurons are associated with several types of glial cells including Schwann cells, which
provide the myelination that increases conduction speeds, as well as satellite glial cells,
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which are found in close association with the neuronal cell bodies and help to modulate
the excitability state of the trigeminal neurons (Thalakoti et al., 2007, Durham and
Garrett, 2010b). A single neuronal cell body is surrounded by several satellite glia,
forming a functional unit that develops during the first few weeks of neonatal
development (Hanani, 2005, Durham and Garrett, 2010a). Importantly, increased
paracrine and gap junction signaling between neurons and glia facilitates and maintains
nociceptor sensitization and is thus implicated in the underlying pathology of migraine
(Durham and Garrett, 2010b).
As the name implies, the TG has three branches that include the ophthalmic, the
maxillary, and the mandibular (Lazarov, 2002) (Fig. 2). The ophthalmic branch (V1)
contains only sensory neurons and serves many structures of the eye, the eyebrow and
forehead region, and the upper sinuses (Shankland, 2001a). The maxillary branch (V2) is
also only sensory in function and innervates all the structures surrounding the maxillary
bone including the lower eyelid, skin of the midfacial region, the mucus membrane of the
nasopharynx, the maxillary sinus, the soft palate and the roof of the mouth (Shankland,
2001b). The mandibular branch (V3) is the largest of the three trigeminal nerve branches
and contains both sensory fibers that innervate the lower jaw and motor fibers that
innervate and control the muscles of mastication (Shankland, 2001c).
The STN receives fibers from all three branches of the TG and contains three
subnuclei: the oralis, interpolaris, and caudalis (Bereiter et al., 2000). The most inferior
of these, the trigeminal nucleus caudalis (TNC) contains neurons involved in processing
nociception from the head and face and is thus implicated in migraine pathology
(Akerman et al., 2011). The second order neurons located in the outer laminas in the TNC
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carry nociceptive signaling received from the TG and transmit it to the thalamus and
cortex (Shankland, 2000). The TNC contains a large glial population, including
astrocytes and microglia. In addition to rapid proliferation following injury, activated glia
produce and release pro-inflammatory molecules that modulate the function and
excitability of nearby neurons by changing the expression of ion channels and receptors
within the plasma membrane (Guo et al., 2007). Throughout the CNS, astrocytes form
networks with each other connected by gap junctions, primarily formed by connexin 43,
which allow the exchange of Ca2+ and other small molecules. Astrocytes have extensive
contact with neuronal synapses as well as cerebral blood vessels, leading to a “tripartite
synapse” theory which suggests that synapses are made up of pre- and post- synaptic
neuronal processes as well as astrocytic processes, allowing the astrocyte network to
modulate neuronal signals (Ji et al., 2013). Microglia, when activated, proliferate and
migrate, undergoing morphological changes that allow them to become phagocytic
(Ohsawa et al., 2004).

Proteins Implicated in Inflammation
Migraine and other neuroinflammatory pathologies involving nociception are
associated with an increased expression of mitogen activated protein (MAP) kinases,
which activate signaling cascades in order to alter gene expression and release
inflammatory mediators. MAP kinase pathways are involved in a diverse range of cell
functions, including differentiation, division, movement, and death, and are thus common
research targets (Schaeffer and Weber, 1999). Two of the most well studied groups of
MAP kinases are extracellular signal-regulated kinase (ERK1/2) and p38. These proteins
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are activated via phosphorylation and then translocate to the nucleus where they activate
transcription factors that directly regulate expression of inflammatory genes involved in
production of cytokines, chemokines, and nitric oxide (Raman et al., 2007).
ERK is strongly activated by nerve growth factor (NGF), which maintains the
nociceptor phenotype and also sensitizes nociceptors and ion channels (Nicol and Vasko,
2007). It has also been suggested that ERK plays an important role in neural plasticity,
which can lead to tactile allodynia or movement-induced pain, both of which are
important features of chronic pain (Ji et al., 2009). ERK may also be involved in long
term potentiation (Xin et al., 2006), an important feature of central sensitization (Ji et al.,
2003).
The signaling protein p38 is activated by cellular stress and proinflammatory
cytokines (Ji et al., 2009). Once activated, p38 translocates to the nucleus and induces the
phosphorylation of transcriptional factors that increase the biosynthesis of inflammatory
mediators such as TNF-α and IL-1β (Ji and Woolf, 2001). In addition, p38 can sensitize
nociceptors posttranslationally, a much faster process than acting on gene expression (Jin
and Gereau, 2006).
Another signaling cascade implicated in the production of inflammatory
mediators involves activation of adenylyl cyclase-cAMP-protein kinase A (PKA)
pathway by numerous inflammatory mediators including the prostaglandin E2 (PGE2)
receptor, the adenosine receptor, and the serotonin (5-hydroxytryptamine or 5-HT)
receptors (Taiwo and Levine, 1991). PKA then modulates and enhances the tetrodotoxinresistant voltage-gated sodium currents that are found primarily in nociceptors, leading to
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sensitization of those nociceptors (Aley and Levine, 1999) and hyperalgesia (Fitzgerald et
al., 1999).
The class of P2X purinoceptors mediate vasoconstriction and contraction of
visceral smooth muscle and are activated by α,β-methylene ATP (Burnstock, 2000). ATP
functions in neuronal signaling by eliciting both fast- and slow-inactivating inward
currents which depolarizes neurons (Xu and Huang, 2002). The subtype P2X3 is located
in both sensory neurons and glia and is expressed in structures associated with pain signal
processing, and thus has been implicated in cranial nociception, particularly through its
association with Transient Receptor Potential V1 (TRPV1), which functions as a signal
integrator downstream of several pro-inflammatory G-protein coupled receptors
(Saloman et al., 2013).
The calcium binding adapter protein Iba1 is often utilized as a marker of activated
microglia within the CNS and a marker of phagocytes within the PNS (Ohsawa et al.,
2004). Elevated levels of Iba1 are associated with inflammatory events such as increased
proliferation and migration as well as an increase in the production and secretion of proinflammatory cytokines and chemokines (Ito et al., 1998), all of which are required for
repairing cellular damage (Kreutzberg, 1996). Microglia are often described as
macrophage-like as they rapidly proliferate and assume immune roles in both the central
and peripheral nervous systems after injury (Ji et al., 2013) and have been shown to play
a role in inflammatory pain (Zhou et al., 2008).
Glial fibrillary acidic protein (GFAP), an intermediate filament protein, is
expressed in astrocytes, which are specialized glial cells that perform multiple functions
within the central nervous system including formation of blood brain barrier and
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modulating synaptic connections between neurons. With respect to nociception,
upregulation of GFAP expression correlates with the state of reactive astrogliosis, or the
astrocyte’s response to injury and as such is used as a biomarker of these cells (Anderson
et al., 2014). Importantly, changes in GFAP are associated with morphological and
biochemical events within astrocytes, which are found in close proximity to neurons and
help to regulate the local extracellular environment and thus, the state of neuronal
excitability.

Migraine Therapies – Dihydroergotamine and Sumatriptan
Ergotamine has been used for the clinical treatment of migraine since the 1920’s,
but its medicinal effects have been known and utilized since the middle ages (Hofmann,
1978). The original source of ergot was the ascomycetous fungus Claviceps purpurea, an
obligate pathogen that infects cultivated cereals, primarily rye. When bread made from
contaminated grains is consumed, the parasite can cause ergotism (also known as St.
Anthony’s Fire), a neurological disease that can manifest as either convulsions and
hallucinations or gangrene and necrosis of the extremities, depending on the strain of
ergot contamination (De Costa, 2002). However, its vasoconstrictive effects were often
utilized by midwives to speed labor and manage post-partum hemorrhages. Ergot extract
was first recommended for migraine treatment in 1868, when it was thought that migraine
was due to hypersympathetic activity, and ergotamine was first isolated in 1918, followed
by many clinical trials showing its efficacy throughout the 1920’s and ‘30’s (TfeltHansen and Koehler, 2008). Ergotamine and its derivatives were then the standard antimigraine drug until the development of the triptan class of drugs in the 1990’s and even
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after the advent of triptans, ergot derivatives may be chosen over a triptan due to their
ability to lower the rate of headache recurrence (Tfelt-Hansen et al., 2000).
Dihydroergotamine (DHE) was synthesized in 1943 and, though originally meant
as an anti-hypertensive agent, was first used to treat migraine in 1945. DHE was shown
to be effective for the treatment of both intermittent and intractable migraine in 1986,
with less nausea and vomiting as well as fewer vasoconstrictor effects than ergotamine
(Silberstein and McCrory, 2003).
Dihydroergotamine belongs to the tetracyclic ergoline family and differs from
ergotamine by the hydrogen found at the 10 position on the tetracyclic ergoline ring (Fig.
3) (Maurer and Frick, 1984). DHE acts as an agonist upon multiple 5-HT (serotonin)
receptor subtypes, α-adrenoreceptors, and dopamine receptors (Perrin, 1985, Cook et al.,
2009, Dahlof and Maassen Van Den Brink, 2012), with more receptors activated when it
is administered via IV vs. an inhaled form (MAP0004). DHE has a much longer
dissociation half-life from serotonin receptors than sumatriptan (Kori et al., 2012),
possibly contributing the lower rate of headache recurrence seen with ergot derivatives.
Dihydroergotamine has been found to inhibit second-order trigeminocervical
neurons in experiments with cats, similar to other proven anti-migraine agents including
several triptans (Hoskin et al., 2004). DHE has also been found to inhibit central
sensitization both when administered at the same time as a prolonged inflammatory
stimulus as well as when administered 2.5 hours after the stimulus (Oshinsky et al.,
2012). This study contrasted DHE with zolmitriptan, which could not inhibit central
sensitization in that model.
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Developed in the early 1990’s as a specific anti-migraine therapy, sumatriptan
was the first of the triptan class of drugs designed to abort an episodic migraine attack. It
is a derivative of a non-ergot alkaloid, called an indole, and was initially developed as a
selective constrictor of intracranial blood vessels (Moskowitz, 1993). Sumatriptan shows
a high specificity for 5-HT1 receptors, specifically the 5-HT1B and 5-HT1D, with a lower
affinity for 5-HT1F receptors (Dahlof and Maassen Van Den Brink, 2012). At
concentrations above that found at clinically relevant doses, sumatriptan will display a
weak affinity for 5-HT1A and 5-HT1E receptors. Sumatriptan has no significant activity at
other 5-HT receptor subtypes or at other non-5-HT receptor types such as adrenergic,
dopaminergic, or histamine receptors.
Along with their vasoconstrictive effects, sumatriptan, DHE, and other 5-HT1
agonists are thought to work through three possible pathways. The first is through
activation of the 5-HT1D receptors on trigeminal nerve terminals that innervate the
meningeal blood vessels, blocking the release of inflammatory neuropeptides. The
second route is through activation of central 5-HT1B//1D//1F receptors in the trigeminal
nuclear caudalis, which blocks transmission of nociception from first order to second
order neurons. The third possible mode of action is via stimulation of 5-HT1B//1D
receptors in the ventroposteromedial thalamus, preventing the processing of nociceptive
input from second order to third order neurons within the thalamus. (Dahlof and
Hargreaves, 1998, Tepper et al., 2002, Dahlof and Maassen Van Den Brink, 2012).
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Goals of Study
The goal of my study was to determine the effect of DHE in an animal model
which mimics trigeminal system pathology associated with chronic migraine and to
compare those effects to the effects of a well-known and widely accepted migraine
treatment, sumatriptan. I wanted to test the hypothesis that DHE, due to its less specific
receptor-binding profile, would be more effective than sumatriptan in blocking
nocifensive behaviors and then determine through immunohistochemistry which
signaling pathways were most effected.
To test this hypothesis, I utilized behavioral and molecular techniques to
investigate the effects of both of these drugs in an established model of chronic
trigeminal nerve activation. Briefly, an inflammatory agent, complete Freund’s adjuvant
(CFA) was injected into the temporomandibular joint capsule to cause sustained
inflammation and activation of the trigeminal system, followed by an intraperitoneal
injection of each of the drugs of interest and then both nocifensive behaviors and cellular
changes were examined. Results from this study suggest that DHE is more effective than
sumatriptan in blocking nocifensive responses and does so by uniquely attenuating
cellular changes in nociceptive pathways. Based on my findings, I propose that DHE
could be a useful alternative for those migraneurs dissatisfied or unresponsive to triptans.
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Figure 1. Nociception pathway through the trigeminal system. From the periphery,
signals are transmitted up primary neurons to the STN in the spinal cord, where the
primary neurons synapse with the secondary neurons. From the STN, the signal is
transmitted to the thalamus and then up tertiary neurons to the sensory cortex.
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Figure 2. The trigeminal nerve. See text for details.
(https://commons.wikimedia.org/wiki/File:Gray778.png#/media/File:Gray778.png)
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Figure 3. Chemical structures of DHE (left) and sumatriptan (right).
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MATERIALS AND METHODS

Animals and Chronic Inflammation Model
All animal procedures in this study were reviewed and approved by the
Institutional Animal Care and Use Committee of Missouri State University (protocol #
14-019.0A approved on 1/27/2014) in accordance with the guidelines established in the
Animal Welfare Act and National Institutes of Health. Every effort was made to
minimize animal suffering and to use the minimum number of animals. Adult male
Sprague-Dawley rats (300–400 g; Charles River Laboratories, Wilmington, MA) were
individually housed in clean plastic cages exposed to a 12-h light/dark cycle (light from
7:00 a.m. to 7:00 p.m.) and allowed unrestricted access to food and water.
As a model to study prolonged trigeminal nerve activation as reported in frequent
and chronic migraine, some rats received bilateral injections in the temporomandibular
joint capsule of 50 µL complete Freund’s adjuvant (CFA; 1:1 CFA/saline; SigmaAldrich, St. Louis, MO). As a control, some rats were injected only with 50 µL of saline.
Injections were administered using a 26½ G needle (Becton Dickinson, Franklin Lakes,
NJ) attached to a 100 µL glass syringe (Hamilton Company, Reno, NV) while the
animals were anaesthetized via inhalation of 3-5% isoflurane (Patterson Veterinary,
Devens, MA).
Three days post-injection of CFA or saline, rats were given intraperitoneal (i.p.)
injections of either dihydroergotamine [DHE; Tocris Bioscience, Bristol, UK; prepared at
a concentration of 50 mg/mL in dimethyl sulfoxide (DMSO) and administered at a
dosage of 10 mg/kg], an equivalent volume of the vehicle DMSO (Sigma-Aldrich), or
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sumatriptan (brand name Alsuma; manufactured at a concentration of 6 mg/0.5 mL and
administered at a dosage of 0.3 mg/kg; Pfizer, New York, NY). See Table 1 for a
summary of experimental conditions and number of animals utilized in my study.
Five days post-injection, animals were sacrificed via inhalation of CO2 followed
by decapitation and tissues were collected for molecular analysis. The animals used for
behavioral testing were sacrificed in the same manner fourteen days post CFA injection.
See Figure 6 for overall timeline of study.

Nocifensive Responses to Mechanical Stimuli
For behavioral testing, animals were first acclimated to the Durham Animal
Holder (Ugo Basile, Varese, Italy) (Fig. 4) for five minutes on three consecutive days
then allowed two days to rest undisturbed before experimental readings were begun.
Acclimation involved placing the animal in the holder and gently rubbing that rat’s face
in the area to be tested with a plastic filament similar to the von Frey filaments so as to
condition the animal to a mechanical stimulus. This minimizes false reactions due to the
animal being startled when measurements are taken at later timepoints during the
experiment.
Nocifensive responses were determined using a series of calibrated von Frey
filaments (60, 100, and 180 g; Ugo Basile) (Fig. 5) applied in increasing force to the
cutaneous area directly over the TMJ. Base line readings were taken on the day prior to
CFA or saline injections and further readings were taken two hours post-injection and
days 3 (prior to i.p. injection), 5, 7, 10, and 14 post-injection. Measurements were
obtained between 8:00 and 10:00 a.m. (with the exception of the two hour post-injection
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time-point). The researcher responsible for the direct application of the filament was
blinded to the experimental conditions.
Data are reported as the mean number of positive responses (a withdrawal of the
animal’s head) out of five applications to each side of the face of 100 g force ± SEM.
Statistical analysis was performed using a factorial ANOVA followed by Tukey’s post
hoc with SPSS 21 software. Differences were considered to be significant at p < 0.05.

Tissue Collection, Preparation, and Immunostaining
Following sacrifice, the upper spinal cord and the trigeminal ganglia were
removed. The spinal cord was trimmed at the obex and 5 mm posterior to the obex,
allowing the area encompassing the spinomedullar junction (Vc/C1) transition zone,
which contains the spinal trigeminal nucleus (STN), to be kept. Tissues were placed in
4% paraformaldehyde for fixation and incubated overnight at 4°C. Tissues were then
cryoprotected by placing them in a 15% sucrose solution and incubated for one hour at
4°C before being moved to a 30% sucrose solution and incubated overnight at 4°C.
Tissues were quickly frozen in Optimal Cutting Temperature medium (OCT;
Sakura Finetek, Torrance, CA) with the dorsal side (ganglia) or posterior side (spinal
cord) facing up. Fourteen micron longitudinal (ganglia) or transverse (spinal cord)
sections were taken using a cryostat (Microm HM 525, Thermo Scientific, Waltham,
MA) set at -24°C and sections were mounted on Superfrost Plus glass slides (Fisher
Scientific, Pittsburgh, PA) then stored at -20°C until utilized for immunohistochemistry.
Each slide contained one section of each experimental condition (Table 1) for that round.
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To minimize non-specific binding of antibodies and permeabilize the tissues,
sections were incubated for twenty minutes in a solution of phosphate buffered saline (1X
PBS; Sigma-Aldrich) that contained 5% donkey serum (Jackson ImmunoResearch, West
Grove, PA) and 0.1% Triton-X (Fisher Scientific, Pittsburgh, PA). Slides were rinsed
with PBS and incubated with primary antibodies diluted in 5% donkey serum for either
three hours at room temperature or overnight at 4°C in a humidity chamber constructed
using a damp paper towel, parafilm, and a pipet tip box. A summary of the antibody
sources, dilutions, and incubation times is provided in Table 2. Slides were then rinsed
with 0.1% Tween 20 solution (Sigma-Aldrich) and incubated with appropriate secondary
Alexa antibodies diluted in PBS for one hour at room temperature. Slides were then
rinsed with 0.1% Tween again, covered with Vectashield Mounting Media (H-1200)
containing 4’6-diamidino-2-phenylin-dole (DAPI; Vector Laboratories, Burlingame, CA)
to co-stain cell nuclei, and covered with a glass coverslip (Fisher Scientific, Pittsburgh,
PA). Slides were stored at 4°C prior to image collection.

Microscopy and Image Analysis
Images (200x) of the medullary horn of the STN and the V3 region of the TG
were collected using a Zeiss Axiocam mRm camera mounted on a Zeiss Imager Z1
fluorescent microscope equipped with an ApoTome. Image acquisition and analysis was
performed using Zeiss Zen Blue 2012 (Thornwood, NY). All images within a set
(meaning those images from sections on a single slide that are from the same round and
immunostained with the same antibody) were balanced so that the non-staining, acellular
regions of the STN or the fiber tracks of the TG appeared to be the same brightness. The
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images were then evaluated using a +/- system as follows: the control tissue was assigned
a value of 0 and all other images within that set were compared to the level and number
of cells positively stained and designated according to the following list:
 0 = No change from control
 + = Increased expression from control (approximately 50%)
 ++ = Dramatically increased expression from control (approximately 100%)
 - = Decreased expression from control (approximately 50%)
 -- = Dramatically decreased expression from control (approximately 100%)
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Table 1. Experimental Conditions and Number of Animals Utilized in Study

DMSO

Behavioral
n Number
6

Molecular
n Number
2

Saline

DHE

6

2

Saline

Sumatriptan

6

2

CFA

DMSO

6

2

CFA

DHE

6

2

CFA

Sumatriptan

6

2

TMJ Injection

i.p. Injection

Saline
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Table 2. Summary of Antibodies and Incubation Conditions
Antibody

Company

Product #

Species Dilution

Incubation

PKA

Epitomics

2113-1

Rabbit

1:500

3 hours, RT

P-p38

Cell Signaling Technology

4511S

Rabbit

1:200

Overnight, 4°C

P-ERK

Bioworld

BS5016

Rabbit

1:200

Overnight, 4°C

GFAP

Abcam

Ab53554

Goat

1:5000

3 hours, RT

Iba1

Wako

019-19741

Rabbit

1:1000

3 hours, RT

P2X3

ThermoScientific

PA1-30936

Rabbit

1:500

Overnight, 4°C

Alexa 488

Invitrogen

A21206

Rabbit

1:200

1 hour, RT

Alexa 568

Invitrogen

A11057

Goat

1:200

1 hour, RT
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Figure 4. A Sprague Dawley rat in the Durham Animal Holder. Slits were cut into the
original holder to facilitate testing sensitivity of trigeminal neurons to a mechanical
stimulus applied in the orofacial region of the rat. The red color of the device prevents
the animal from seeing the approach of the von Frey filaments and thus reduces nonevoked withdrawal responses.
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Figure 5. A 60 gram (left) and 100 gram (right) Von Frey filament. These filaments were
used to evoke a withdrawal response when applied to the orofacial region of the rat. A
positive withdrawal response was associated with bending of the filament.
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Figure 6. Experimental timeline. * = CFA or saline injection in TMJ, # = i.p. treatment
injection, XM = animals sacrificed for molecular studies, XB = animals from behavioral
studies sacrificed, A = behavioral acclimations, BL = base line behavioral readings taken,
underlined numbers = days on which further behavioral readings were taken (note that
the day 3 readings were taken prior to administration of treatment injections).
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RESULTS

Effect of Dihydroergotamine and Sumatriptan on Nocifensive Response
Administration of DMSO, which served as a vehicle control for drug delivery, on
days 3 and 4 post-saline injection did not elevate mean nocifensive responses above 2 out
of 5 (Fig. 7). Responses of animals that were injected with saline, which served as a
vehicle control of CFA, and then administered sumatriptan did not differ significantly
from those of the DMSO group at any timepoint. In contrast, animals that received the
saline injection and were then administered DHE did have significantly fewer nocifensive
responses than the DMSO group on day 5 (p = 0.040), which corresponds to the
timepoint on the day immediately following the DHE administration. No further
significant differences were found between experimental conditions at any later
timepoints.
Following injection of CFA into the TMJ, nocifensive responses were
significantly elevated as compared to the group that received saline injections (p = 0.005
on day 5, p < 0.001 at all other timepoints after CFA injection) (Fig. 8). Administration
of sumatriptan on days 3 and 4 post CFA injection did not significantly affect nocifensive
responses as compared to those that were administered DMSO at any timepoint.
Administration of DHE on days 3 and 4 significantly lowered nocifensive responses on
day 5 (p = 0.005) as compared to the DMSO group. However, this effect was transient as
no significant differences were seen for the remainder of the timepoints investigated.
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Suppression of PKA Expression in the STN by Dihydroergotamine
All sections were examined using the nuclear stain DAPI, which fluorescently
marks the nuclei of all cells. No differences in DAPI distribution were seen between any
treatment conditions (data not shown). A representative image is shown in Figure 9,
illustrating the overall cellular morphology as well as the area of interest to which all
further STN images will be confined.
Within the control tissue, active PKA expression was localized in a narrow,
somewhat diffuse band along the dorsal horn of the STN (Fig. 10). Injection of DHE
following saline injection within the TMJ resulted in a much lighter and more diffuse
band, suggesting a downregulation of basal PKA expression. Injection of sumatriptan
following saline injection had no effect, with PKA staining pattern similar to that of
control tissue.
Injection of CFA in the TMJ resulted in a robust increase in active PKA
expression with a bright, discrete band along the medullary horn (outer laminas)
surrounded by a wider band of bright and diffuse staining. Injection of DHE following
CFA injection greatly lowered PKA expression to below that of even control levels, with
no discernable discrete band and only dim, diffuse staining along the horn. In contrast,
injection of sumatriptan following CFA injection resulted in a level of PKA expression
that appears lower than that seen in the CFA and DMSO tissues, but is still more intense
than the levels in control tissue.
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P2X3 Expression is Repressed in the STN by Dihydroergotamine and Sumatriptan
Within the control tissue, P2X3 expression was limited to a diffuse band along the
horn with sporadic brighter areas of intensity (Fig. 11). Treatment with DHE following
saline injection in the TMJ diminishes those bright areas, leaving only a diffuse band of
staining. Treatment with sumatriptan following saline injection reduced the intensity of
staining in the outer laminas as compared to control tissue.
Injection of CFA in the TMJ resulted in a very bright band of staining along the
dorsal horn with numerous bright areas of staining. Treatment with DHE following the
CFA injection brought the expression level down to near control levels, with a diffuse
band of staining and sporadic bright areas. Treatment with sumatriptan following CFA
injection inhibited the staining intensity, leaving only a diffuse band in the outer laminas.

P-ERK Expression is Downregulated in the STN by Dihydroergotamine
Within the control tissue, there was little to no P-ERK staining visible, with only a
few neurons expressing active levels of P-ERK (Fig. 12). Treatment with DHE or
sumatriptan following saline injection did not change the staining appearance.
Injection of CFA in the TMJ resulted in a robust increase in the number of
neuronal cells expressing elevated levels of P-ERK within the dorsal horn. Treatment
with DHE following CFA injection reduced the number of P-ERK-positive neurons, but
there was still a greater number than in the control tissues. Treatment with sumatriptan
following CFA injection appeared to have no effect on P-ERK expression as the staining
pattern was similar to that seen in the CFA sample.
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Repression of CFA-Stimulated Iba1 Expression in the STN by Dihydroergotamine
Within the control tissue, Iba1 expression, which is a biomarker of activated
microglia, was faint, limited to a handful of glial cells along the dorsal horn (Fig. 13).
Treatment with DHE following saline injection moderately increased Iba1 expression, as
did treatment with sumatriptan following saline injection.
Injection of CFA in the TMJ greatly increased the number of activated microglial
cells in the dorsal horn. Treatment with DHE following CFA injection repressed Iba1
levels down to near control levels. Treatment with sumatriptan following CFA injection
somewhat reduced the number of activated glial cells as compared to the CFA sample,
but to a lesser extent than did the DHE treatment.

GFAP Expression is Inhibited in the STN by Dihydroergotamine and Sumatriptan
Within the control tissue, GFAP expression was observed in a sparse band of
activated astrocytes within the dorsal horn (Fig. 14). Treatment with DHE following
saline injection greatly reduced basal GFAP staining intensity and number of GFAP
expression astrocytes, as did treatment with sumatriptan following saline injection.
Injection of CFA in the TMJ increased the number of active astrocytes, while
treatment with DHE and sumatriptan both greatly reduced the intensity of staining to
below control levels.

Repression of P2X3 Expression in the TG by Dihydroergotamine and Sumatriptan
All sections were examined using the nuclear stain DAPI, which fluorescently
marks the nuclei of all cells. No differences in DAPI distribution were seen between any
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treatment conditions (data not shown). A representative image is shown in figure 15,
illustrating the overall cellular morphology as well as the area of interest to which all
further TG images will be confined.
Within the control tissue, there was very little P2X3 staining (Fig. 16A). Neither
administration of DHE nor sumatriptan had an effect on the staining intensity.
CFA injection in the TMJ dramatically increased the amount of P2X3 staining,
with numerous large- and small-diameter neurons showing fluorescent staining (Fig.
16B). Treatment with DHE and sumatriptan each reduced the amount of staining as
compared to the CFA sample, but not to the low levels of the control tissue.

Dihydroergotamine Inhibits CFA-Induced P-ERK Expression in the TG
There was very little P-ERK staining in the control tissue, mainly faint
fluorescence in the cytoplasm of neurons (Fig. 17A). Treatment with DHE following
saline injection had no effect on ERK expression. Treatment with sumatriptan following
saline injection, on the other hand, slightly upregulated ERK expression with some
neurons showing ERK expression within the nucleus.
Following CFA injection, ERK expression was upregulated, with several neurons
showing ERK expression within the nucleus (Fig. 17B). Treatment with DHE following
CFA injection resulted in ERK expression similar to that of the control tissue. Treatment
with sumatriptan following CFA injection had no effect on ERK expression, resulting in
a staining pattern and intensity similar to that of the CFA sample.
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Active p38 Expression is Downregulated in the TG by Dihydroergotamine
Within the control tissue, a small amount of neurons show P-p38 staining within
the nucleus, a sign of activated P-p38 (Fig. 18A). Treatment with dihydroergotamine
reduced this staining, with no visible neurons showing nuclear staining. Treatment with
sumatriptan following saline injection resulted in a staining pattern similar to that seen in
the control tissue.
Injection of CFA in the TMJ upregulated P-p38 expression, with the majority of
neurons showing nuclear staining (Fig. 18B). Treatment with DHE and sumatriptan
resulted in staining patterns similar to that seen in the control tissue, with only a few
neurons showing nuclear staining.

Iba1 Expression is Downregulated in the TG by Dihydroergotamine and
Sumatriptan
Within the control tissue, a moderate number of glial cells brightly fluoresced
(Fig. 19A). Treatment with DHE and sumatriptan each reduced the intensity of
fluorescence in the glial cells.
Following CFA injection in the TMJ, more glial cells brightly fluoresced as
compared to the control tissue (Fig. 19B). Administration of DHE following CFA
injection greatly reduced the number of glial cells showing fluorescence as well as the
intensity of fluorescence. Administration of sumatriptan following CFA injection slightly
reduced the intensity of fluorescence, displaying a similar pattern and brightness to that
of the samples administered sumatriptan following saline injection.
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Figure 7. Effect of DHE and sumatriptan on basal responses. Treatment with DHE
significantly inhibited nocifensive responses as compared to vehicle only on day 5.
Values are reported as the average number of withdrawal responses to mechanical
stimulation out of 5 applications to each side using a 100 g von Frey filament. * p =
0.040.
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Figure 8. Effect of DHE and sumatriptan on nocifensive responses following CFA
injection. CFA mediated sustained and significant nocifensive responses beginning 2
hours after injection and continuing for 14 days. Treatment with DHE following CFA
injection significantly inhibited nocifensive responses on day 5. Values are reported as
the average number of withdrawal responses to mechanical stimulation out of 5
applications to each side using a 100 g von Frey filament. # p < 0.05. * p = 0.005.
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Figure 9. TNC morphology. A view of a full TNC slice stained with DAPI (top) and an
enlarged view of the area of interest (bottom), which is outlined in white in the top image.

32

Figure 10. PKA expression in the STN. DHE inhibits both basal levels of PKA
expression as well as CFA-induced increases in PKA expression. Sumatriptan had no
effect on basal PKA expression and only somewhat inhibited CFA-induced increases in
PKA expression. Spinal cords were removed as described five days after saline or CFA
injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3
and 4 post-saline/CFA injection. Lower table displays changes in relative staining
intensity (n = 2 independent experiments).
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Figure 11. P2X3 expression in the STN. DHE and sumatriptan each inhibited basal P2X3
expression. Sumatriptan inhibited CFA-induced increases in P2X3 expression to a greater
extent than DHE. Spinal cords were removed as described five days after saline or CFA
injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3
and 4 post-saline/CFA injection. Lower table displays changes in relative staining
intensity (n = 2 independent experiments).
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Figure 12. P-ERK expression in the STN. Neither DHE nor sumatriptan had an effect on
basal P-ERK expression. DHE somewhat inhibited CFA-induced increases in P-ERK
expression while sumatriptan had no effect. Spinal cords were removed as described five
days after saline or CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p.
injections occurring on days 3 and 4 post-saline/CFA injection. Lower table displays
changes in relative staining intensity (n = 2 independent experiments).
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Figure 13. Iba1 expression in the STN. DHE and sumatriptan treatment resulted in a
slight increase in basal Iba1 expression. DHE greatly inhibited CFA-mediated Iba1
increases while sumatriptan only somewhat inhibited CFA-mediated Iba1 increases.
Spinal cords were removed as described five days after saline or CFA injection in the
TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 and 4 postsaline/CFA injection. Lower table displays changes in relative staining intensity (n = 2
independent experiments).
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Figure 14. GFAP expression in the STN. DHE and sumatriptan each greatly inhibited
both basal GFAP expression as well as CFA-mediated increases in GFAP expression.
Spinal cords were removed as described five days after saline or CFA injection in the
TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 and 4 postsaline/CFA injection. Lower table displays changes in relative staining intensity (n = 2
independent experiments).
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Figure 15. TG morphology. Full image of a TG slice stained with DAPI (top). Area
outlined in white is enlarged in bottom left. Area outlined in white in bottom left image is
enlarged in bottom right.
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Figure 16. P2X3 expression in the TG. (A) Neither DHE nor sumatriptan had an effect on
basal P2X3 expression in the TG. (B) DHE and sumatriptan each somewhat inhibited
CFA-mediated increases in P2X3 expression in the TG. Ganglia were removed as
described five days after saline or CFA injection in the TMJ with DMSO, DHE, or
sumatriptan i.p. injections occurring on days 3 and 4 post-saline/CFA injection. Lower
table displays changes in relative staining intensity (n = 2 independent experiments).
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Figure 17. P-ERK expression in the TG. (A) DHE had no effect on basal P-ERK
expression while sumatriptan slightly upregulated basal P-ERK expression. (B) DHE
inhibited CFA-mediated increases in P-ERK expression. Sumatriptan had no effect on
CFA-mediated increases. Ganglia were removed as described five days after saline or
CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on
days 3 and 4 post-saline/CFA injection. Lower table displays changes in relative staining
intensity (n = 2 independent experiments).
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Figure 18. Active p38 expression in the TG. (A) DHE greatly decreased basal P-p38
expression while sumatriptan had no effect. (B) DHE and sumatriptan each inhibited
CFA-mediated increases in P-p38 expression. Ganglia were removed as described five
days after saline or CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p.
injections occurring on days 3 and 4 post-saline/CFA injection. Lower tables display
staining intensity as determined by previously described guidelines.
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Figure 19. Iba1 expression in the TG. (A) DHE and sumatriptan each decreased basal
Iba1 expression in the TG. (B) DHE greatly inhibited CFA-mediated increases in Iba1
expression, while sumatriptan only somewhat decreased it. Ganglia were removed as
described five days after saline or CFA injection in the TMJ with DMSO, DHE, or
sumatriptan i.p. injections occurring on days 3 and 4 post-saline/CFA injection. Lower
table displays changes in relative staining intensity (n = 2 independent experiments).
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DISCUSSION

DHE Represses Nocifensive Responses to Mechanical Stimulation
The major finding from my study is that DHE, but not sumatriptan, was
effective in blocking nociception associated with prolonged inflammation and sustained
trigeminal neuron activation. I hypothesized based on receptor binding profiles and a
previous study in our laboratory (Masterson and Durham, 2010) that DHE may function
by a different mechanism of action than sumatriptan, and therefore may be beneficial in
decreasing nociception caused by persistent trigeminal nociceptor activation. The
differential ability of DHE and sumtriptan to modulate responses to mechanical
stimulation likely lies in their different pharmacological profiles. DHE predominantly
acts as a pan-amine receptor agonist while sumatriptan binds selectively and with high
affinity to the 5-HT1B and 5-HT1D receptors. Similar to the triptans, DHE is known to
bind to the serotonin 5-HT1B and 5-HT1D receptors (Goadsby, 2000, Cook et al., 2009).
However, the potency of DHE binding to the different receptors depends on maximum
plasma concentration (Cmax) achieved by the different routes of administration used for
therapeutic purposes. When 1 mg of DHE is administered via IV, Cmax is about 45,289
pg/mL, effective binding includes 8 serotonin receptors, 4 α-adrenoceptors, and 2
dopamine receptors and, as a result, DHE IV treatment is associated with a number of
unwanted side effects. When administered through oral inhalation (MAP0004, 6
actuations, 1.8 mg per dose), the Cmax is about 5,241 pg/mL and effective bindings
include only 4 serotonin receptors, 3 α-adrenoceptors, and 1 dopamine receptor and, as a
result, some of the common side effects of the IV dosing were not reported. My finding
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that sumatriptan was not inhibitory in the CFA-induced trigeminal activation model was
unexpected. It should be noted that DHE only mediated a transient inhibitory effect on
mechanical sensitivity of trigeminal primary neurons with a significant decrease in
withdrawal responses on day 5 following DHE treatment on days 3 and 4. On day 7, the
average number of nocifensive responses was similar to that observed in the CFA alone
treated animals. Thus, it appears that a sustained inflammatory stimulus, as occurs in
response to CFA injection into the TMJ capsule, results in a pathological condition of
trigeminal activation that cannot be reversed by only two treatments of DHE. Based on
my results, I can only speculate that DHE would need to be administered on a daily basis
to be an effective therapy for frequent episodic or chronic migraine.
My finding that sumatriptan could not inhibit ongoing peripheral and central
sensitization of trigeminal nociceptive neurons differs from the results published by
Burstein and Jakubowski (Burstein and Jakubowski, 2004). In their experiment, the
investigators used a rat model in which intracranial pain is used to induce cutaneous
allodynia, a manifestation of central sensitization of the STN, to measure the effects of
treatment with triptans given either before initiation of central sensitization or after it is
established. Using this model, these researchers found that concomitant administration of
sumatriptan and an inflammatory soup (IS), containing 1 mM histamine, serotonin,
bradykinin, and 0.1 mM prostaglandin E2 in 10 mM HEPES buffer, pH 5.5, is applied to
the dura mater effectively blocked the development of central sensitization. Specifically,
experimental evidence included the lack of expansion of dural receptive fields or increase
in dural indentation sensitivity, a lack of long-term spontaneous firing increases, and no
increase in the magnitude of response to mechanical or thermal skin stimulation in central
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trigeminovascular neurons. Sumatriptan, administered after the establishment of central
sensitization, reversed intracranial sensitivity of central trigeminovascular neurons, as
evidenced by a reversal of IS-induced dural receptive field expansion and neuronal
sensitivity to dural stimulation; however, it did not reverse the increased neuronal
sensitivity to mechanical or thermal stimulation at the periorbital skin or the increased
spontaneous firing. These findings suggest that the anti-nociceptive effects of triptans are
mediated largely through pre-synaptic inhibition of transmitters release in the dorsal horn
by the peripheral nociceptors, rather than post-synaptic inhibition of receptors on central
trigeminovascular neurons (Oshinsky et al., 2012). In another study using the same
animal model, the effects of zolmitriptan and DHE were compared on the generation and
maintenance of central sensitization. Zolmitriptan administered 1 hour before or 2.5
hours after application of an IS to the dura mater did not inhibit central sensitization, as
measured electrophysiologically, in the STN. In contrast, DHE given either before or at
the time of IS application to the dura mater was able to block the induction of central
sensitization. When given after central sensitization of the TNC was established, DHE
was able to reverse sensory thresholds to brush, pin, and pressure stimulation. These
results suggest that DHE and triptans act by different mechanisms of action once central
sensitization is established and that DHE, unlike a triptan, reverses central sensitization
(Oshinsky et al., 2012). The difference in the ability of DHE to reverse central
sensitization is most likely due to the transient nature of the stimulus used in their study
when compared to the persistent stimulus used in my model of trigeminal activation.
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DHE Differentially Regulates Cellular Pathways
Results from my study provide evidence at the cellular level to help explain why
administration of DHE on days 3 and 4 was sufficient to inhibit the nocifensive effect of
CFA in response to mechanical stimulation. DHE was found to inhibit the CFAstimulated increase in STN expression of PKA, P2X3, P-ERK, Iba1, and GFAP, which
are all proteins implicated in the development and maintenance of central sensitization.
In addition, DHE also repressed the stimulatory effect of CFA on P2X3, P-ERK, P-p38,
and Iba1 in the trigeminal ganglion. Each of these proteins is involved in modulating the
excitability state of primary sensory trigeminal neurons. For example, increased
expression of the active phosphorylated form of the MAP kinase signaling protein ERK
is associated with sensitization of primary and secondary nociceptive neurons that
facilitates prolonged nociception (Dai et al., 2002, Ji, 2004). Elevated levels of MAP
kinases such as ERK and P38 promote and sustain neuronal sensitization by modulating
the expression of receptors and ion channels, stimulating release of inflammatory
molecules, and facilitating interactions with glial cells (Ji et al., 2009). Similarly to our
previous observations (Cady et al., 2014), I found that CFA injection in the TMJ
increased the expression of Iba1, a protein used as a biomarker of activated macrophage
cells (Nakamura et al., 2013), within the functional units of the ganglia. Our finding of
increased activation of macrophages in response to CFA-induced inflammation within the
TMJ is in agreement with the results of previous studies involving trigeminal nerve
activation caused by inflammatory stimuli (Villa et al., 2010, Franceschini et al., 2013).
An increase in the activity level of macrophages within the ganglion is likely to facilitate
the inflammatory response via the release of cytokines and other mediators and to
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function as scavengers to remove cellular debris caused during pathology. CFA also
mediated an increase in Iba1 expression in microglia within the STN. Activated
microglial cells are known to increase the synthesis and release of pro-inflammatory
mediators including cytokines and chemokines.
In agreement with results from our previous study (Cady et al., 2014), I found that
CFA injection in the TMJ resulted in an upregulation of PKA expression within the STN.
Elevated levels of PKA modulate nociceptive responses of primary neurons by enhancing
sodium currents, sensitizing nociceptors. This pathway is activated by CGRP, which has
been shown to be released in response to peripheral tissue injury (Seybold, 2009). Once
CGRP binds to its receptor, which is located on neuronal cell bodies, astrocytes, and
microglia, the concentration of the secondary messenger cAMP increases, resulting in
activation of PKA. Activated PKA promotes and sustains central sensitization by
phosphorylating proteins that regulate the excitability state of both neurons and glia. I
also observed an increase in the level of P2X3 expression in both the STN and TG. P2X3
receptors, which are abundantly expressed by TG neurons projecting to the dura (Durham
and Garrett, 2010b) and upon activation by ATP are known to mediate acute and chronic
pain (Durham and Russo, 2003, Olesen et al., 2004, Levy et al., 2005, Bowen et al., 2006,
Bigal et al., 2007). Similarly to my finding with DHE, results from another study using
the selective P2X3 receptor antagonist A-317491 have provided evidence that blocking
P2X3 receptors was effective in repressing nociception in inflammatory and neuropathic
pain models (Vause et al., 2007). This effect is not surprising since ATP activation of
P2X3 receptors was shown to promote sensitization of primary afferent nociceptors
involved in development of hyperalgesia (Cady et al., 2010). Finally, I also observed an
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increase in the expression of the structural protein GFAP, which is associated with
activated astrocytes (Anderson et al., 2014). The development and maintenance of
peripheral and central sensitization of nociceptive neurons has been shown to be
dependent on activated astrocytes (Watkins et al., 2001).
Although I found that all of these proteins were downregulated by DHE following
CFA injection, the expression levels of many of them were also inhibited by sumatriptan.
Only ERK and Iba1 were downregulated to a greater extent by DHE than by sumatriptan
in both the ganglion and the spinal cord, while PKA was downregulated to a greater
extent by DHE in the spinal cord. Thus, I propose that decreased expression of these
particular proteins are likely responsible for the inhibitory effect of DHE on nocifensive
withdrawal responses following prolonged trigeminal activation. In support of this
notion, blocking ERK and PKA activation in nociceptive neurons and activation of
microglia are associated with a decrease in the inflammatory response and promotes an
anti-nocifensive state within animals (Aley and Levine, 1999, Watkins and Maier, 2002,
Ji et al., 2009).
My results provide evidence that DHE induces cellular changes that are distinct
from those induced by sumatriptan. This observation is in agreement with previous
results from our laboratory in which DHE, but not sumatriptan, repressed ATP-mediated
sensitization of trigeminal ganglion neurons (Masterson and Durham, 2010). In that
study, neonatal rat trigeminal ganglia cultures were used to investigate effects of ATP,
alpha, beta-methyl ATP (α,β-meATP), and DHE on intracellular calcium levels and
calcitonin gene-related peptide (CGRP) secretion. Pretreatment with ATP or α,β-meATP
caused sensitization of neurons, via P2X3 receptors, such that a subthreshold amount of
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potassium chloride (KCl) significantly increased intracellular calcium levels and CGRP
secretion. Pretreatment with DHE repressed increases in calcium and CGRP secretion in
response to ATP-KCl or α,β -meATP-KCl treatment. Importantly, these inhibitory
effects of DHE were blocked with an α2-adrenoceptor antagonist and unaffected by a
5HT1B/D receptor antagonist. DHE also decreased neuronal membrane expression of the
P2X3 receptor. Results from that study provided evidence for a novel mechanism of
action for DHE that involves blocking ATP mediated sensitization of trigeminal neurons,
repressing stimulated CGRP release, and decreasing P2X3 membrane expression via
activation of α2-adrenoceptors. Further evidence that DHE may function differently
from the triptans was provided by data showing that DHE treatment of trigeminal
neurons did not change intracellular calcium levels as previously reported for the triptans.
(Durham and Russo, 1999, 2003) While DHE repression of potassium chloride–
stimulated release of CGRP from ATP-sensitized trigeminal neurons involved inhibition
of intracellular calcium levels by decreasing membrane expression of the P2X3 receptor
(Masterson and Durham, 2010), studies on sumatriptan demonstrated that its inhibitory
effects were mediated via activation of 5-HT1 receptors. (Durham and Russo, 1999,
2003).

Summary and Future Directions
In summation, my study showed that DHE but not sumatriptan can transiently
block nocifensive responses to mechanical stimulation following CFA-mediated chronic
inflammation. This is likely due to a different mechanism of action, as suggested by my
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immunohistochemical results, which showed that DHE differentially regulates ERK,
Iba1, and PKA.
Due to the transitory nature of its effects, DHE may be more helpful in treating
frequent episodic migraine than chronic migraine, and thus prevent patients from
progressing to chronic migraine. In fact, the best indicator of the likelihood of a patient
developing chronic migraine is the frequency of their episodic migraines (Schwedt,
2014). Once a patient’s migraines become chronic, the only currently FDA-approved
treatment is injection with Botox, so preventing that chronification should be a priority
for sufferers of episodic migraine. Currently, sumatriptan is the most commonly
prescribed migraine treatment, but approximately 30% of patients do not get satisfactory
results from it (Mathew, 2001). My results suggest that since DHE works through
different pathways than sumatriptan, it could be a good potential alternative for that
subpopulation of patients. Another advantage of DHE over the use of triptans is that
DHE has been reported to cause minimal constriction of human cerebral arteries in
vivo—significantly less than caused by triptans (Nilsson et al., 1999). DHE did not have
any vasoconstrictor effects on the porcine middle meningeal artery (Mehrotra et al.,
2006) but did cause vasoconstriction of the perfused middle cerebral artery of rats (TfeltHansen et al., 2007). DHE was reported to increase resistance of the meningeal vascular
bed in anesthetized cats (Lambert and Michalicek, 1996). Evaluation of the effect of
DHE in vitro on distal and proximal coronary arteries demonstrated no significant
vasoconstriction (Labruijere et al., 2015). Taken together, the results of human and
animal studies show that DHE has variable and condition-dependent effects on cerebral
and peripheral arteries and veins. As with other acute migraine therapies, there is no
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direct evidence that vasoconstriction plays a primary role in the therapeutic effects of
DHE.
In the future, it may be beneficial to look at several different iterations of the
model presented in my study to determine the best efficacy of DHE. Some possibilities
include pre-treating with DHE prior to initiation of inflammation, continuing daily
treatment throughout the course of the study, or increasing the doses of DHE and
sumatriptan.
Given the increasing prevalence and socio-economic impact of more frequent
migraine attacks and the lack of effective medications to inhibit the progression from
frequent to chronic migraine, more effective therapeutic approaches are in great need for
this group of migraine sufferers. Towards this end, a new method to deliver DHE in an
aerosolized form that is rapidly absorbed by the lungs and minimizes unwanted side
effects caused by oral or injectable administration of DHE is in development by the
pharmaceutical company Allergan, and awaiting approval from the Food and Drug
Administration.

51

REFERENCES

Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in
migraine. Nature reviews Neuroscience 12:570-584.
Aley KO, Levine JD (1999) Role of protein kinase A in the maintenance of inflammatory
pain. J Neurosci 19:2181-2186.
Anderson MA, Ao Y, Sofroniew MV (2014) Heterogeneity of reactive astrocytes.
Neurosci Lett 565:23-29.
Bereiter DA, Hirata H, Hu JW (2000) Trigeminal subnucleus caudalis: beyond
homologies with the spinal dorsal horn. Pain 88:221-224.
Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C (2007) Satisfaction with
current migraine therapy: experience from 3 centers in US and Sweden. Headache
47:475-479.
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain
activity triggers trigeminal meningeal afferents in a migraine model. Nature
medicine 8:136-142.
Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL (2006) Tumor necrosis factoralpha stimulation of calcitonin gene-related peptide expression and secretion from
rat trigeminal ganglion neurons. J Neurochem 96:65-77.
Burnstock G (2000) P2X receptors in sensory neurones. Br J Anaesth 84:476-488.
Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of
intracranial pain: a race against the development of central sensitization. Annals
of neurology 55:27-36.
Cady RJ, Denson JE, Sullivan LQ, Durham PL (2014) Dual orexin receptor antagonist 12
inhibits expression of proteins in neurons and glia implicated in peripheral and
central sensitization. Neuroscience 269:79-92.
Cady RJ, Hirst JJ, Durham PL (2010) Dietary grape seed polyphenols repress neuron and
glia activation in trigeminal ganglion and trigeminal nucleus caudalis. Mol Pain
6:91.
Cook RO, Shrewsbury SB, Ramadan NM (2009) Reduced adverse event profile of orally
inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 49:14231434.

52

Dahlof C, Maassen Van Den Brink A (2012) Dihydroergotamine, ergotamine,
methysergide and sumatriptan - basic science in relation to migraine treatment.
Headache 52:707-714.
Dahlof CG, Hargreaves RJ (1998) Pathophysiology and pharmacology of migraine. Is
there a place for antiemetics in future treatment strategies? Cephalalgia 18:593604.
Dai Y, Iwata K, Fukuoka T, Kondo E, Tokunaga A, Yamanaka H, Tachibana T, Liu Y,
Noguchi K (2002) Phosphorylation of extracellular signal-regulated kinase in
primary afferent neurons by noxious stimuli and its involvement in peripheral
sensitization. J Neurosci 22:7737-7745.
De Costa C (2002) St Anthony's fire and living ligatures: a short history of ergometrine.
Lancet 359:1768-1770.
Devor M (1999) Unexplained peculiarities of the dorsal root ganglion. Pain Suppl 6:S2735.
Dodick D, Silberstein S (2006) Central sensitization theory of migraine: clinical
implications. Headache 46 Suppl 4:S182-191.
Dodick DW (2009) Review of comorbidities and risk factors for the development of
migraine complications (infarct and chronic migraine). Cephalalgia 29 Suppl 3:714.
Durham PL, Garrett FG (2010a) Development of functional units within trigeminal
ganglia correlates with increased expression of proteins involved in neuron-glia
interactions. Neuron glia biology 6:171-181.
Durham PL, Garrett FG (2010b) Emerging importance of neuron-satellite glia
interactions within trigeminal ganglia in craniofacial pain. Open Pain J 3:3-13.
Durham PL, Russo AF (1999) Regulation of calcitonin gene-related peptide secretion by
a serotonergic antimigraine drug. J Neurosci 19:3423-3429.
Durham PL, Russo AF (2003) Stimulation of the calcitonin gene-related peptide enhancer
by mitogen-activated protein kinases and repression by an antimigraine drug in
trigeminal ganglia neurons. J Neurosci 23:807-815.
Fitzgerald EM, Okuse K, Wood JN, Dolphin AC, Moss SJ (1999) cAMP-dependent
phosphorylation of the tetrodotoxin-resistant voltage-dependent sodium channel
SNS. J Physiol 516 ( Pt 2):433-446.
Franceschini A, Vilotti S, Ferrari MD, van den Maagdenberg AM, Nistri A, Fabbretti E
(2013) TNFalpha levels and macrophages expression reflect an inflammatory

53

potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine.
PLoS One 8:e52394.
Goadsby PJ (2000) The pharmacology of headache. Progress in neurobiology 62:509525.
Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, Wei F, Dubner R, Ren
K (2007) Glial-cytokine-neuronal interactions underlying the mechanisms of
persistent pain. J Neurosci 27:6006-6018.
Hanani M (2005) Satellite glial cells in sensory ganglia: from form to function. Brain Res
Brain Res Rev 48:457-476.
Hofmann A (1978) Historical view on ergot alkaloids. Pharmacology 16 Suppl 1:1-11.
Hoskin KL, Lambert GA, Donaldson C, Zagami AS (2004) The 5hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit
trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res
998:91-99.
Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S (1998) Microgliaspecific localisation of a novel calcium binding protein, Iba1. Brain research
Molecular brain research 57:1-9.
Ji RR (2004) Peripheral and central mechanisms of inflammatory pain, with emphasis on
MAP kinases. Curr Drug Targets Inflamm Allergy 3:299-303.
Ji RR, Berta T, Nedergaard M (2013) Glia and pain: is chronic pain a gliopathy? Pain 154
Suppl 1:S10-28.
Ji RR, Gereau RWt, Malcangio M, Strichartz GR (2009) MAP kinase and pain. Brain
research reviews 60:135-148.
Ji RR, Kohno T, Moore KA, Woolf CJ (2003) Central sensitization and LTP: do pain and
memory share similar mechanisms? Trends Neurosci 26:696-705.
Ji RR, Woolf CJ (2001) Neuronal plasticity and signal transduction in nociceptive
neurons: implications for the initiation and maintenance of pathological pain.
Neurobiology of disease 8:1-10.
Jin X, Gereau RWt (2006) Acute p38-mediated modulation of tetrodotoxin-resistant
sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J
Neurosci 26:246-255.
Kori S, Kellerman DJ, Voloshko P, Haugen G (2012) Effects of a supratherapeutic dose
of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a

54

randomized, double-blind, active- and placebo-controlled crossover study in
healthy volunteers. Clinical therapeutics 34:1920-1928.
Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends
Neurosci 19:312-318.
Labruijere S, Chan KY, de Vries R, van den Bogaerdt AJ, Dirven CM, Danser AJ, Kori
SH, MaassenVanDenBrink A (2015) Dihydroergotamine and sumatriptan in
isolated human coronary artery, middle meningeal artery and saphenous vein.
Cephalalgia 35:182-189.
Lambert G, Michalicek J (1996) Effect of antimigraine drugs on dural blood flows and
resistances and the responses to trigeminal stimulation. Eur J Pharmacol 311:141151.
Lazarov NE (2002) Comparative analysis of the chemical neuroanatomy of the
mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Progress
in neurobiology 66:19-59.
Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not
excite or sensitize meningeal nociceptors: implications for the pathophysiology of
migraine. Annals of neurology 58:698-705.
Masterson CG, Durham PL (2010) DHE repression of ATP-mediated sensitization of
trigeminal ganglion neurons. Headache 50:1424-1439.
Mathew NT (2001) Pathophysiology, epidemiology, and impact of migraine. Clin
Cornerstone 4:1-17.
Maurer G, Frick W (1984) Elucidation of the structure and receptor binding studies of the
major primary, metabolite of dihydroergotamine in man. European journal of
clinical pharmacology 26:463-470.
Mehrotra S, Gupta S, Garrelds IM, Villalon CM, Saxena PR, Bogers AJ,
Maassenvandenbrink A (2006) Effects of current and prospective antimigraine
drugs on the porcine isolated meningeal artery. Naunyn Schmiedebergs Arch
Pharmacol 374:163-175.
Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment
of migraine. Neurology 43:S16-20.
Nakamura R, Nishimura T, Ochiai T, Nakada S, Nagatani M, Ogasawara H (2013)
Availability of a microglia and macrophage marker, iba-1, for differential
diagnosis of spontaneous malignant reticuloses from astrocytomas in rats. Journal
of toxicologic pathology 26:55-60.

55

Nicol GD, Vasko MR (2007) Unraveling the story of NGF-mediated sensitization of
nociceptive sensory neurons: ON or OFF the Trks? Molecular interventions 7:2641.
Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L (1999) Contractile 5-HT1B
receptors in human cerebral arteries: pharmacological characterization and
localization with immunocytochemistry. Br J Pharmacol 128:1133-1140.
Ohsawa K, Imai Y, Sasaki Y, Kohsaka S (2004) Microglia/macrophage-specific protein
Iba1 binds to fimbrin and enhances its actin-bundling activity. Journal of
neurochemistry 88:844-856.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM
(2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the
acute treatment of migraine. The New England journal of medicine 350:11041110.
Oshinsky ML, Sanghvi MM, Maxwell CR, Gonzalez D, Spangenberg RJ, Cooper M,
Silberstein SD (2012) Spontaneous trigeminal allodynia in rats: a model of
primary headache. Headache 52:1336-1349.
Perrin VL (1985) Clinical pharmacokinetics of ergotamine in migraine and cluster
headache. Clinical pharmacokinetics 10:334-352.
Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. Annual review of
physiology 75:365-391.
Raman M, Chen W, Cobb MH (2007) Differential regulation and properties of MAPKs.
Oncogene 26:3100-3112.
Rathee PK, Distler C, Obreja O, Neuhuber W, Wang GK, Wang SY, Nau C, Kress M
(2002) PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to
thermal hyperalgesia. J Neurosci 22:4740-4745.
Saloman JL, Chung MK, Ro JY (2013) P2X(3) and TRPV1 functionally interact and
mediate sensitization of trigeminal sensory neurons. Neuroscience 232:226-238.
Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages
from ubiquitous messengers. Mol Cell Biol 19:2435-2444.
Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416.
Seybold VS (2009) The role of peptides in central sensitization. Handb Exp Pharmacol
451-491.

56

Shankland WE (2001a) The trigeminal nerve. Part II: the ophthalmic division. Cranio
19:8-12.
Shankland WE, 2nd (2000) The trigeminal nerve. Part I: An over-view. Cranio 18:238248.
Shankland WE, 2nd (2001b) The trigeminal nerve. Part III: The maxillary division.
Cranio 19:78-83.
Shankland WE, 2nd (2001c) The trigeminal nerve. Part IV: the mandibular division.
Cranio 19:153-161.
Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history,
pharmacology, and efficacy. Headache 43:144-166.
Smitherman TA, Burch R, Sheikh H, Loder E (2013) The prevalence, impact, and
treatment of migraine and severe headaches in the United States: a review of
statistics from national surveillance studies. Headache 53:427-436.
Taiwo YO, Levine JD (1991) Further confirmation of the role of adenyl cyclase and of
cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience
44:131-135.
Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D
receptor agonists. Archives of neurology 59:1084-1088.
Tfelt-Hansen P, Nilsson E, Edvinsson L (2007) Contractile responses to ergotamine and
dihydroergotamine in the perfused middle cerebral artery of rat. The journal of
headache and pain 8:83-89.
Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H,
Schoenen J, Ferrari MD, Goadsby PJ (2000) Ergotamine in the acute treatment of
migraine: a review and European consensus. Brain : a journal of neurology 123 (
Pt 1):9-18.
Tfelt-Hansen PC, Koehler PJ (2008) History of the use of ergotamine and
dihydroergotamine in migraine from 1906 and onward. Cephalalgia 28:877-886.
Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL
(2007) Neuron-glia signaling in trigeminal ganglion: implications for migraine
pathology. Headache 47:1008-1023.
Vause C, Bowen E, Spierings E, Durham P (2007) Effect of carbon dioxide on calcitonin
gene-related peptide secretion from trigeminal neurons. Headache 47:1385-1397.

57

Villa G, Ceruti S, Zanardelli M, Magni G, Jasmin L, Ohara PT, Abbracchio MP (2010)
Temporomandibular joint inflammation activates glial and immune cells in both
the trigeminal ganglia and in the spinal trigeminal nucleus. Mol Pain 6:89.
Watkins LR, Maier SF (2002) Beyond neurons: evidence that immune and glial cells
contribute to pathological pain states. Physiol Rev 82:981-1011.
Watkins LR, Milligan ED, Maier SF (2001) Spinal cord glia: new players in pain. Pain
93:201-205.
Xin WJ, Gong QJ, Xu JT, Yang HW, Zang Y, Zhang T, Li YY, Liu XG (2006) Role of
phosphorylation of ERK in induction and maintenance of LTP of the C-fiber
evoked field potentials in spinal dorsal horn. Journal of neuroscience research
84:934-943.
Xu GY, Huang LY (2002) Peripheral inflammation sensitizes P2X receptor-mediated
responses in rat dorsal root ganglion neurons. J Neurosci 22:93-102.
Xu GY, Wang F, Jiang X, Tao J (2010) Aquaporin 1, a potential therapeutic target for
migraine with aura. Mol Pain 6:68.
Zhou Z, Peng X, Hao S, Fink DJ, Mata M (2008) HSV-mediated transfer of interleukin10 reduces inflammatory pain through modulation of membrane tumor necrosis
factor alpha in spinal cord microglia. Gene therapy 15:183-190.

58

